Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

Eligibility criteria:
Inclusion Criteria:

          -  Individuals aged ≥ 18 years with upper GI symptoms (epigastric pain/burning, bloating,
             heart-burn, excessive belching, nausea/vomiting, anemia, and/or weight loss)
             appropriate for an upper endoscopy evaluation

          -  Able to speak English

          -  Able to understand and sign consent form

          -  Able to undergo standard outpatient endoscopy

          -  Indications for traditional EGD in the next 30 days

               -  Low blood (Unexplained anemia)

               -  Blood in vomit (Hematemesis)

               -  Upper abdominal or chest pain

               -  Indigestion (Dyspepsia)

               -  GERD

               -  Suspected ulcers

               -  Unexplained weight loss

               -  Gastric Biopsy

               -  Other

        Exclusion Criteria:

          -  Hemodynamic shock

          -  Active hematemesis

          -  Dysphagia, swallowing disorder, Zenker's diverticulum, suspected bowel obstruction or
             perforation, gastroparesis, gastric outlet obstruction, Crohn's disease, prior GI
             tract surgery that changes the gastrointestinal anatomy (e.g., Billroth I or II,
             esophagectomy, gastrectomy, bariatric procedure and small intestinal resection)

          -  Presumed pregnant, trying to conceive or currently breastfeeding

          -  Altered mental status (e.g., hepatic encephalopathy) that limits the ability to
             swallow a capsule

          -  Expected to have Magnetic Resonance Imaging examination within 30 days

          -  Currently (<12 hours) on medications that may coat the upper GI tract such as antacids
             or sucralfate or Maalox

          -  No reliable contact information--no phone, no permanent address

          -  ASA status of more than 3

          -  Implanted with a cardiac pacemaker or other implantable electronic medical device
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment